**ECNP Meeting: Neuropsychopharmacology across Brain Diseases**  
9-10 March 2010, Nice, France

**Programme**  
Per session there are 3 presentations of each 15 minutes, followed by a discussion of 45 minutes.

**Tuesday 9 March 2010**

14.00 - 14.15  **Opening remarks**  
David Nutt, United Kingdom

14.15 - 15.45  **S.01 Anticonvulsants/mood stabilisers**  
Chair: David Nutt, United Kingdom

Psychiatry perspective:  
Bipolar disorders  
Eduard Vieta, Spain

Neurology perspective:  
Anticonvulsants: mood stabilisers, but not anti-epileptics  
Mathias J. Koepp, United Kingdom

Basic research/drug development:  
Developing novel, improved therapeutics for mood disorders  
Guy Goodwin, United Kingdom

15.45 - 16.00  **Break**

16.00 - 17.30  **S.02 Dopamine function enhancing drugs**  
Chair: Jan M. van Ree, The Netherlands  
Discussants: Marc Laruelle, United Kingdom  
David Nutt, United Kingdom

Psychiatry perspective:  
ADHD  
David Heal, United Kingdom

Neurology perspective:  
Dopamine agonists in Parkinson's disease  
Walter Pirker, Austria

Basic research/drug development:  
Dopamine agonists in experimental Parkinsonism and depression-like states  
Per Svenningsson, Sweden

17.30 - 17.45  **Break**

17.45 - 19.15  **S.03 Cognition enhancers**  
Chair: Per Svenningsson, Sweden  
Discussants: James Nicoll, United Kingdom  
Tim Tully, USA

Psychiatry perspective:  
The brave new world of cognitive enhancers: industry perspective  
Marc Laruelle, United Kingdom

Neurology perspective:  
Translational aspect in Alzheimer's disease  
Thomas Bayer, Germany

Basic research/drug development:  
Tau-based drug discovery for Alzheimer's Disease  
Michael Hutton, United Kingdom

19.15 - 21.15  **Dinner**
Wednesday 10 March 2010

09.00 - 10.30

S.04  Opioids
Chair: David Nutt, United Kingdom
Discussants: Guy Simonnet, France
             Helge Waal, Norway

Psychiatry perspective:
The role of opioids in the treatment of addiction: past experiences and future possibilities
Wim van den Brink, The Netherlands

Neurology perspective:
Opioids in neuropathic pain
Michael Ossipov, USA

Basic research/drug development:
Chronic exposure to drugs of abuse induces long-term transcriptional deregulation in the central extended amygdala
Katia Befort, France

10.30 - 10.45 Break

10.45 - 12.15

S.05  Neurostimulation techniques
Chair: Per Svenningsson, Sweden
Discussants: Andrea L. Malizia, United Kingdom
              Veerle Visser-Vandewalle, The Netherlands

Psychiatry perspective:
Deep brain stimulation in psychiatry - evidence, neurobiology and perspectives
Damiaan Denys, The Netherlands

Neurology perspective:
Brain stimulation in neurological disorders
Stéphane Palfi, France

Basic research/drug development:
Neurobiological effects of deep brain stimulation in animal models
Trevor Sharp, United Kingdom

12.15 - 14.00 Lunch

14.00 - 15.30

S.06  Genetics and connectivity
Chair: David Nutt, United Kingdom
Discussant: Andrea Malizia, United Kingdom

Psychiatry perspective:
Autism: a connectivity disorder?
Anthony J. Bailey, United Kingdom

Neurology perspective:
Neurotrophic factors and connectivity problems in neurodegenerative disorders
Mart Saarma, Finland

Basic research/drug development:
Aberrant functional connectivity in genetic animal models of hyperdopaminergia and NMDA receptor hypofunction
Raul R. Gainetdinov, Italy

15.30 - 15.45 Break

15.45 - 17.15

S.07  Antidepressants
Chair: Per Svenningsson, Sweden
Discussant: Enrico Domenici, Italy

Psychiatry perspective:
Depression
Erkki Isometsä, Finland
Neurology perspective: Depression and stroke recognition and management
Jill Rasmussen, United Kingdom

Basic research/drug development: Antidepressants and plasticity
Eero Castrén, Finland

17.15 - 17.30 Break

17.30 - 19.00 Gene therapy
Chair: David Nutt, United Kingdom
Discussants: Esa Korpi, Finland
Mart Saarma, Finland

Psychiatry perspective: Mental retardation: towards targeted treatment of the fragile X syndrome
R. Frank Kooy, Belgium

Neurology perspective: Gene therapy for Parkinson’s disease: progress and prospects
Anders Björklund, Sweden

Basic research/drug development: Viral vectors to manipulate gene expression
William Wisden, United Kingdom

19.00 - 19.30 Closing remarks
Jan van Ree, The Netherlands

19.30 - 21.30 Dinner